scholarly journals The Gene Encoding Protocadherin 9 (PCDH9), a Novel Risk Factor for Major Depressive Disorder

2017 ◽  
Vol 43 (5) ◽  
pp. 1128-1137 ◽  
Author(s):  
Xiao Xiao ◽  
Fanfan Zheng ◽  
Hong Chang ◽  
Yina Ma ◽  
Yong-Gang Yao ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Gene Encoding

Erectile Dysfunction is a Modifiable Risk Factor for Major Depressive Disorder: Analysis of a Federated Research Network

2021 ◽  
Vol 18 (12) ◽  
pp. 2005-2011
Author(s):  
Sirpi Nackeeran ◽  
Amoghavarsha Havanur ◽  
Jesse Ory ◽  
Stanley Althof ◽  
Ranjith Ramasamy
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Erectile Dysfunction ◽  
Depressive Disorder ◽  
Research Network ◽  
Modifiable Risk Factor ◽  
Major Depressive

Major Depressive Disorder as an Occult Risk Factor for Postoperative Cardiac Complications

2009 ◽  
Vol 249 (2) ◽  
pp. 354
Author(s):  
Laurel A. Copeland ◽  
Valerie A. Lawrence ◽  
John E. Zeber
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Cardiac Complications ◽  
Major Depressive

Factors associated with frovatriptan response in patients with migraine: A prospective, observational study

Cephalalgia ◽  
2015 ◽  
Vol 36 (5) ◽  
pp. 493-498 ◽  
Author(s):  
Jong-Geun Seo ◽  
Sung-Pa Park
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Observational Study ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Odds Ratio ◽  
Prospective Observational Study ◽  
Major Depressive ◽  
Factors Associated ◽  
Headache Clinic

Background Almost one-third of patients with migraine do not adequately respond to triptans. We examined factors contributing to frovatriptan response in patients with migraine. Methods We enrolled new patients with migraine who consecutively visited our headache clinic. Eligible patients were instructed to take 2.5 mg of frovatriptan as soon as possible after migraine attack. The responsiveness was determined by whether headache was relieved or absent within 4 hours after the intake of frovatriptan. We assessed frovatriptan to be efficacious when headache responded to its administration in at least one of two successive migraine attacks and inefficacious when headache was not relieved in either attack. We included demographic, clinical and psychiatric variables in the analysis of factors associated with frovatriptan response. Results Of 128 eligible patients, 28 (21.9%) experienced frovatriptan inefficacy. In 24 patients with current major depressive disorder, 12 (50.0%) had frovatriptan inefficacy. Only current major depressive disorder was identified as a risk factor for inefficacy (odds ratio = 5.500, 95% confidence interval 2.103–14.382, p = 0.001). Conclusions Depression may be a risk factor of frovatriptan inefficacy in patients with migraine, even though half of patients with major depressive disorder respond to frovatriptan.

Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population

2012 ◽  
Vol 46 (4) ◽  
pp. 555-559 ◽  
Author(s):  
Takashi Fujii ◽  
Miho Ota ◽  
Hiroaki Hori ◽  
Daimei Sasayama ◽  
Kotaro Hattori ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Japanese Population ◽  
Functional Polymorphism ◽  
Major Depressive ◽  
Gene Encoding ◽  
P Glycoprotein

scholarly journals Joint reanalysis of 29 correlated SNPs supports the role of PCLO/Piccolo as a causal risk factor for major depressive disorder

2009 ◽  
Vol 14 (7) ◽  
pp. 650-652 ◽  
Author(s):  
Z Bochdanovits ◽  
M Verhage ◽  
A B Smit ◽  
E J C de Geus ◽  
D Posthuma ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Causal Risk Factor

scholarly journals Tobacco smoking as a risk factor for major depressive disorder: population-based study

2008 ◽  
Vol 193 (4) ◽  
pp. 322-326 ◽  
Author(s):  
Julie A. Pasco ◽  
Lana J. Williams ◽  
Felice N. Jacka ◽  
Felicity Ng ◽  
Margaret J. Henry ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
De Novo ◽  
Population Based ◽  
Major Depressive ◽  
Cross Sectional ◽  
History Of ◽  
Study Designs

BackgroundSmoking is disproportionately prevalent among people with psychiatric illness.AimsTo investigate smoking as a risk factor for major depressive disorder.MethodA population-based sample of women was studied using case–control and retrospective cohort study designs. Exposure to smoking was self-reported, and major depressive disorder diagnosed using the Structured Clinical Interview for DSM–IV–TR (SCID–I/NP).ResultsAmong 165 people with major depressive disorder and 806 controls, smoking was associated with increased odds for major depressive disorder (age-adjusted odds ratio (OR)=1.46, 95% CI 1.03–2.07). Compared with non-smokers, odds for major depressive disorder more than doubled for heavy smokers (>20 cigarettes/day). Among 671 women with no history of major depressive disorder at baseline, 13 of 87 smokers and 38 of 584 non-smokers developedde novomajor depressive disorder during a decade of follow-up. Smoking increased major depressive disorder risk by 93% (hazard ratio (HR)=1.93, 95% CI 1.02–3.69); this was not explained by physical activity or alcohol consumption.ConclusionsEvidence from cross-sectional and longitudinal data suggests that smoking increases the risk of major depressive disorder in women.

The Four-Year Course of Major Depressive Disorder: The Role of Staging and Risk Factor Determination

2014 ◽  
Vol 83 (5) ◽  
pp. 279-288 ◽  
Author(s):  
Lynn Boschloo ◽  
Robert A. Schoevers ◽  
Aartjan T.F. Beekman ◽  
Johannes H. Smit ◽  
Albert M. van Hemert ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Depressive Disorder ◽  
Major Depressive
Sign in / Sign up

Export Citation Format

Share Document